IP-10在呼吸系统疾病中的研究进展
Research Advances of IP-10 in Respiratory Diseases
DOI: 10.12677/acm.2025.15123506, PDF,   
作者: 黄 珊, 杨林瀛*：承德医学院附属医院呼吸与危重症医学科，河北 承德
关键词: IP-10；趋化因子；呼吸系统疾病；IP-10； Chemokine； Respiratory Diseases
摘要: 干扰素诱导蛋白10 (interferon inducible protein 10, IP-10)归属于Cys-X-Cys (CXC)趋化因子家族，能够通过与其特异性受体CXCR3相互作用，引导Th1淋巴细胞、自然杀伤细胞及单核巨噬细胞等免疫细胞定向迁移，在多种呼吸系统疾病的免疫调控与炎症应答过程中发挥重要作用。正常生理状态下，IP-10通过调控炎症反应与免疫平衡，参与呼吸道黏膜防御体系，而在肺部感染性疾病、慢性阻塞性肺疾病、支气管哮喘、肺纤维化及急性呼吸窘迫综合征等病理状态下，其表达水平显著异常，成为打破免疫稳态的关键介质。本文旨在系统阐述IP-10的生物学特征，并探讨其在呼吸系统疾病发生发展过程中的功能及其潜在临床应用意义，从而为相关疾病的诊治策略提供科学参考。
Abstract: Interferon-inducible protein 10 (IP-10), a member of the Cys-X-Cys (CXC) chemokine family, interacts with its specific receptor CXCR3 to direct the migration of immune cells such as Th1 lymphocytes, natural killer cells, and monocyte-macrophages. It plays a critical role in immune regulation and inflammatory responses in various respiratory diseases. Under normal physiological conditions, IP-10 contributes to the defense system of the respiratory mucosa by modulating inflammatory reactions and immune balance. However, in pathological states such as pulmonary infectious diseases, chronic obstructive pulmonary disease, bronchial asthma, pulmonary fibrosis, and acute respiratory distress syndrome, its expression levels become significantly dysregulated, making it a key mediator in disrupting immune homeostasis. This article systematically elaborates on the biological characteristics of IP-10 and explores its functions in the pathogenesis and progression of respiratory diseases, as well as its potential clinical implications, thereby providing a scientific reference for the diagnosis and treatment of related diseases.
文章引用：黄珊, 杨林瀛. IP-10在呼吸系统疾病中的研究进展[J]. 临床医学进展, 2025, 15(12): 1083-1090. https://doi.org/10.12677/acm.2025.15123506

参考文献

[1] Luster, A.D. and Ravetch, J.V. (1987) Genomic Characterization of a γ-Interferon-Inducible Gene (IP-10) and Identification of an Interferon-Inducible Hypersensitive Site. Molecular and Cellular Biology, 7, 3723-3731. [Google Scholar] [CrossRef] 
[2] Liu, M., Guo, S., Hibbert, J.M., Jain, V., Singh, N., Wilson, N.O., et al. (2011) CXCL10/IP-10 in Infectious Diseases Pathogenesis and Potential Therapeutic Implications. Cytokine & Growth Factor Reviews, 22, 121-130. [Google Scholar] [CrossRef] [PubMed]
[3] Ichikawa, A., Kuba, K., Morita, M., Chida, S., Tezuka, H., Hara, H., et al. (2013) CXCL10-CXCR3 Enhances the Development of Neutrophil-Mediated Fulminant Lung Injury of Viral and Nonviral Origin. American Journal of Respiratory and Critical Care Medicine, 187, 65-77. [Google Scholar] [CrossRef] [PubMed]
[4] Lang, S., Li, L., Wang, X., Sun, J., Xue, X., Xiao, Y., et al. (2017) CXCL10/IP-10 Neutralization Can Ameliorate Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Rats. PLOS ONE, 12, e0169100. [Google Scholar] [CrossRef] [PubMed]
[5] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版) [J]. 中华结核和呼吸杂志, 2016, 39(4): 253-279.
[6] 周玲, 张霞, 费海莹, 等. 血清CXCL10水平与社区获得性肺炎严重程度及预后的关系[J]. 东南大学学报(医学版), 2023, 42(4): 553-559.
[7] Xu, C., Luo, L., Wu, B., Ding, N., Jin, S., Huang, J., et al. (2024) Diagnostic Values of Soluble Triggering Receptor Expressed on Myeloid Cells (sTREM-1) and Interferon-Inducible Protein-10 (IP-10) for Severe Mycoplasma Pneumoniae Pneumonia in Children. Clinics, 79, Article ID: 100361. [Google Scholar] [CrossRef] [PubMed]
[8] Zou, Y., Huang, F., Sun, J., Zheng, Y., Dai, G., Wang, T., et al. (2025) The Role of IFN-γ/CXCL10 Axis in Mycoplasma Pneumonia Infection. Scientific Reports, 15, Article No. 2671. [Google Scholar] [CrossRef] [PubMed]
[9] Zeng, X., Moore, T.A., Newstead, M.W., Deng, J.C., Kunkel, S.L., Luster, A.D., et al. (2005) Interferon-Inducible Protein 10, but Not Monokine Induced by γ Interferon, Promotes Protective Type 1 Immunity in Murine Klebsiella pneumoniae Pneumonia. Infection and Immunity, 73, 8226-8236. [Google Scholar] [CrossRef] [PubMed]
[10] Haroun, R.A., Osman, W.H. and Eessa, A.M. (2021) Interferon-γ-Induced Protein 10 (IP-10) and Serum Amyloid a (SAA) Are Excellent Biomarkers for the Prediction of COVID-19 Progression and Severity. Life Sciences, 269, Article ID: 119019. [Google Scholar] [CrossRef] [PubMed]
[11] Samaras, C., Kyriazopoulou, E., Poulakou, G., Reiner, E., Kosmidou, M., Karanika, I., et al. (2023) Interferon γ-Induced Protein 10 (IP-10) for the Early Prognosis of the Risk for Severe Respiratory Failure and Death in COVID-19 Pneumonia. Cytokine, 162, Article ID: 156111. [Google Scholar] [CrossRef] [PubMed]
[12] Hachem, H., Godara, A., Schroeder, C., Fein, D., Mann, H., Lawlor, C., et al. (2021) Rapid and Sustained Decline in CXCL-10 (IP-10) Annotates Clinical Outcomes Following TNFα-Antagonist Therapy in Hospitalized Patients with Severe and Critical COVID-19 Respiratory Failure. Journal of Clinical and Translational Science, 5, e146. [Google Scholar] [CrossRef] [PubMed]
[13] Ruhwald, M., Bjerregaard-Andersen, M., Rabna, P., Kofoed, K., Eugen-Olsen, J. and Ravn, P. (2007) CXCL10/IP-10 Release Is Induced by Incubation of Whole Blood from Tuberculosis Patients with ESAT-6, CFP10 and Tb7.7. Microbes and Infection, 9, 806-812. [Google Scholar] [CrossRef] [PubMed]
[14] Zhao, Y., Yang, X., Zhang, X., Yu, Q., Zhao, P., Wang, J., et al. (2018) IP-10 and RANTES as Biomarkers for Pulmonary Tuberculosis Diagnosis and Monitoring. Tuberculosis, 111, 45-53. [Google Scholar] [CrossRef] [PubMed]
[15] Strzelak, A., Komorowska-Piotrowska, A., Borowa, A., Krasińska, M., Feleszko, W. and Kulus, M. (2024) IP-10 for the Diagnosis and Treatment Monitoring of Tuberculosis in Children. Diagnostics, 14, Article 177. [Google Scholar] [CrossRef] [PubMed]
[16] Vanini, V., Petruccioli, E., Gioia, C., Cuzzi, G., Orchi, N., Rianda, A., et al. (2012) IP-10 Is an Additional Marker for Tuberculosis (TB) Detection in HIV-Infected Persons in a Low-TB Endemic Country. Journal of Infection, 65, 49-59. [Google Scholar] [CrossRef] [PubMed]
[17] Tang, Y., Yu, Y., Wang, Q., Wen, Z., Song, R., Li, Y., et al. (2023) Evaluation of the IP-10 mRNA Release Assay for Diagnosis of TB in HIV-Infected Individuals. Frontiers in Cellular and Infection Microbiology, 13, Article 1152665. [Google Scholar] [CrossRef] [PubMed]
[18] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007年修订版) [J]. 中华结核和呼吸杂志, 2007, 30(1): 8-17.
[19] Lin, T., Chen, W., Ding, Z., Wei, S., Huang, M. and Li, C. (2019) Correlations between Serum Amyloid A, C‐Reactive Protein and Clinical Indices of Patients with Acutely Exacerbated Chronic Obstructive Pulmonary Disease. Journal of Clinical Laboratory Analysis, 33, e22831. [Google Scholar] [CrossRef] [PubMed]
[20] Grumelli, S., Corry, D.B., Song, L., Song, L., Green, L., Huh, J., et al. (2004) An Immune Basis for Lung Parenchymal Destruction in Chronic Obstructive Pulmonary Disease and Emphysema. PLOS Medicine, 1, e8. [Google Scholar] [CrossRef] [PubMed]
[21] Hardaker, E.L., Bacon, A.M., Carlson, K., Roshak, A.K., Foley, J.J., Schmidt, D.B., et al. (2003) Regulation of TNF‐α and IFN‐γ Induced CXCL10 Expression: Participation of the Airway Smooth Muscle in the Pulmonary Inflammatory Response in Chronic Obstructive Pulmonary Disease. The FASEB Journal, 18, 191-193. [Google Scholar] [CrossRef] [PubMed]
[22] Osman, H.M., El Basha, N.R., Mansour, A.F. and Hanna, M.O.F. (2021) Serum IFNγ-Induced Protein 10 (IP10/CXCL10): Association with Asthma Exacerbations and Severity in Children. Journal of Asthma, 59, 2135-2142. [Google Scholar] [CrossRef] [PubMed]
[23] Ghebre, M.A., Pang, P.H., Desai, D., Hargadon, B., Newby, C., Woods, J., et al. (2019) Severe Exacerbations in Moderate-to-Severe Asthmatics Are Associated with Increased Pro-Inflammatory and Type 1 Mediators in Sputum and Serum. BMC Pulmonary Medicine, 19, Article No. 144. [Google Scholar] [CrossRef] [PubMed]
[24] Arikoglu, T., Akyilmaz, E., Yildirim, D.D., Batmaz, S.B., Ulger, S.T., Aslan, G., et al. (2017) The Relation of Innate and Adaptive Immunity with Viral-Induced Acute Asthma Attacks: Focusing on IP-10 and Cathelicidin. Allergologia et Immunopathologia, 45, 160-168. [Google Scholar] [CrossRef] [PubMed]
[25] Bradding, P., Walls, A.F. and Holgate, S.T. (2006) The Role of the Mast Cell in the Pathophysiology of Asthma. Journal of Allergy and Clinical Immunology, 117, 1277-1284. [Google Scholar] [CrossRef] [PubMed]
[26] Ebert, C., Walsh, A.M., Sereda, L., Wilson, C.L., Schafer, P.H., Fischer, A., et al. (2024) Circulating Biomarker Analyses in a Longitudinal Cohort of Patients with IPF. American Journal of Physiology-Lung Cellular and Molecular Physiology, 326, L303-L312. [Google Scholar] [CrossRef] [PubMed]
[27] Tager, A.M., Kradin, R.L., LaCamera, P., Bercury, S.D., Campanella, G.S.V., Leary, C.P., et al. (2004) Inhibition of Pulmonary Fibrosis by the Chemokine IP-10/CXCL10. American Journal of Respiratory Cell and Molecular Biology, 31, 395-404. [Google Scholar] [CrossRef] [PubMed]
[28] Coward, W.R., Watts, K., Feghali-Bostwick, C.A., Jenkins, G. and Pang, L. (2010) Repression of IP-10 by Interactions between Histone Deacetylation and Hypermethylation in Idiopathic Pulmonary Fibrosis. Molecular and Cellular Biology, 30, 2874-2886. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, W., Yang, P., Zhong, Y., Zhao, Z., Xing, L., Zhao, Y., et al. (2013) Monoclonal Antibody against CXCL-10/IP-10 Ameliorates Influenza a (H1N1) Virus Induced Acute Lung Injury. Cell Research, 23, 577-580. [Google Scholar] [CrossRef] [PubMed]

为你推荐